Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Liabilities (2020 - 2025)

Foghorn Therapeutics has reported Total Liabilities over the past 6 years, most recently at $306.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $306.6 million for Q4 2025, down 6.95% from a year ago — trailing twelve months through Dec 2025 was $306.6 million (down 6.95% YoY), and the annual figure for FY2025 was $306.6 million, down 6.95%.
  • Total Liabilities for Q4 2025 was $306.6 million at Foghorn Therapeutics, up from $294.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for FHTX hit a ceiling of $422.9 million in Q4 2021 and a floor of $104.3 million in Q2 2021.
  • Median Total Liabilities over the past 5 years was $347.7 million (2024), compared with a mean of $324.1 million.
  • Biggest five-year swings in Total Liabilities: soared 297.15% in 2022 and later decreased 12.49% in 2025.
  • Foghorn Therapeutics' Total Liabilities stood at $422.9 million in 2021, then decreased by 4.29% to $404.8 million in 2022, then dropped by 10.29% to $363.1 million in 2023, then fell by 9.25% to $329.5 million in 2024, then dropped by 6.95% to $306.6 million in 2025.
  • The last three reported values for Total Liabilities were $306.6 million (Q4 2025), $294.6 million (Q3 2025), and $302.9 million (Q2 2025) per Business Quant data.